(4R,9aS)-5-hydroxy-2-methyl-6,10-dioxo-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-7-carboxylic acid- 2,4 difluorobenzylamide,
dolutegravir,
dolutegravir sodium,
dolutegravir sodium monohydrate,
GSK 1349572A,
GSK-1349572,
GSK1349572A,
S-GSK1349572,
Tivicay,
DOLUTEGRAVIR SODIUM,
1051375-19-9,
GSK 1349572A,
UNII-1Q1V9V5WYQ,
Dolutegravir (sodium),
GSK1349572 sodiuM salt,
CHEBI:76007,
GSK1349572A,
1Q1V9V5WYQ,
GSK-1349572A,
Tivicay (TN),
Dolutegravir Sodium ( API),
Sodium (4R,12aS)-9-((2,4-difluorobenzyl)carbamoyl)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazin-7-olate;Sodium (4R,12aS)-9-((2,4-difluorobenzyl)carbamoyl)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazin-7-olate,
Dolutegravir sodium [USAN],
dolutegravir-sodium,
AK174049,
CHEMBL1213165,
SCHEMBL19859120,
Dolutegravir sodium (JAN/USAN),
BCP11890,
EX-A1694,
sodium (4R,12aS)-9-[(2,4-difluorobenzyl)carbamoyl]-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazin-7-olate,
HY-13238A,
s4642,
AKOS025396662,
CS-3496,
KS-00000T34,
B5856,
FT-0697030,
D10113,
GSK1349572sodiuMsalt;DOLUTEGRAVIRSODIUM;GSK1349572A;Dolutegravir sodiuM salt;Dolutegravir SodiuM ( API),
Tivicay,
Dolutegravir,
GSK1349572,
ACN-041354,